Revvity, Inc.: stock overview

RVTYNYSEHealthcare · Laboratory Analytical Instruments

Price

$154.39

November 13, 2026Market cap $17.3B

DCF calculator

What Ploutos Investor adds for Revvity

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from FY2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Revvity had revenue of $2.9B over the last 12 months and net income of $253M, a net margin of 8.6%. Revenue grew by 1.4% a year on average over the last 5 years. At $154.39 the shares trade at a P/E of 68.2, against a median of 31.2 over the last 5 fiscal years. It has net debt of $2.0B. It pays a dividend yielding 0.18%.

From its SEC filings (latest fiscal year to December 28, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$17.3B
112M shares
P/E
68.2
Today68.2
Median31.2
Revenue, 12 months
$2.9B
+1.4% a year over 5 years
Net margin
8.6%
FY2025: 8.5%, above 65% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–FY2025 fiscal years

+1.9% a year over 2 years

  • FY2025Dec 28, 202510-K
    Revenue$2.9B
  • FY2024Dec 29, 202410-K
    Revenue$2.8B
  • 202310-K
    Revenue$2.8B

Fiscal years in figures

RVTY's revenue, profit, cash flow and dividend with each year-end price, from FY2009 to FY2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $13.5B
$17.3B
Enterprise value 
$19.3B
P/E 3-year median: 46.7
68.2
EV / EBIT 
51.9
EV / Revenue 
6.6
P/B 3-year median: 1.7
2.4
FCF yield 3-year median: 4.0%
3.4%
Earnings yield 3-year median: 2.1%
1.5%

Profitability

Operating margin 
12.7%
Net margin 3-year median: 9.8%
8.6%
ROIC 
3.2%
ROIC, 5-year average 
4.1%
ROE 
3.5%

Growth

Revenue, yearly change 
+3.7%
EPS, yearly change 
-5.9%
FCF, yearly change 
-5.9%
Revenue, average a year 
+1.4%
EPS, average a year 
-20.4%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$593M
Total debt 
$2.8B
Of which operating leases 
$131M
Net debt 
$2.0B
Net debt / EBITDA 
2.6x
Interest cover 
4.0x
Current ratio 
2.65

Balance sheet of October 4, 2026.

Returns to shareholders

Dividend yield 3-year median: 0.3%
0.18%
Buybacks 
4.76%
Total returned 
4.94%
Shares, yearly change 
-7.0%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 38).

Operating margin

12.5%

Above 67% of the 186 companies in its industry, and 70% of all.

Net margin

8.5%

Above 65% of the 189 companies in its industry, and 62% of all.

ROE

3.3%

Above 54% of the 174 companies in its industry, and 39% of all.

ROA

2.0%

Above 57% of the 190 companies in its industry, and 54% of all.

Revenue growth

3.7%

Above 35% of the 186 companies in its industry, and 41% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
REVVITY, INC.
CIK
31791
Exchange
NYSE
Industry (SIC)
3826 · Laboratory Analytical Instruments
Fiscal year ends
December 29
Latest annual report
December 28, 2025
Reporting currency
USD
Shares
112M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Revvity's filings show?

These are Revvity's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about RVTY

Didn't find what you were looking for?

Ask us
What is RVTY's market cap?

Revvity, Inc.'s market cap is $17.3B, at a price of $154.39 on November 13, 2026 and 112M shares.

What is RVTY's P/E?

RVTY's P/E is 68.2, on earnings per share of $2.25 over the last 12 months. The median over the last 5 fiscal years was 31.2.

How much revenue does RVTY have?

Revvity had revenue of $2.9B over the last 12 months. Over the last 5 years it changed by +1.4% a year on average.

Does RVTY pay a dividend?

Yes. Revvity paid $0.28 per share over the last 12 months, a yield of 0.18% at today's price. All the figures are in the Dividend section.

Where do the figures come from?

From Revvity, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.